The objective of the collaboration is to promote new drug development wherein HUYA will assist in the evaluation of research and development projects conducted by pharmaceutical enterprises residing in Biolake.
HUYA will also globalize select programs from Biolake through its innovative co-development model and worldwide pharmaceutical partners.
HUYA China CTO and COO Clement Gingras said that working with Biolake to identify and accelerate promising product opportunities will further China’s pharmaceutical innovation in accordance with international standards.
Wuhan National Bio-industry Base deputy vice director Zhongning Yan said that partnering with HUYA will enhance its effort to become an international bio-industry cluster, which will benefit the collaborators and partners of both organizations.
Wuhan National Bio-industry Base (Biolake) supports biopharmaceutical industry development in Wuhan East Lake High-Tech Development Zone (WEHDZ).
It is a national-level industry base located at the Wuhan East Lake Hi-tech Development Zone in Wuhan, the capital of the Hubei province. Many academic and research institutions are located here.